These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18166738)

  • 1. Corticosteroids and erythropoeitin-receptor agonists.
    McLachlan CS
    CMAJ; 2008 Jan; 178(1):66. PubMed ID: 18166738
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 3. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia.
    Winquist E; Julian JA; Moore MJ; Nabid A; Sathya J; Wood L; Venner P; Levine M
    J Clin Oncol; 2009 Feb; 27(4):644-6. PubMed ID: 19103725
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials.
    Zarychanski R; Turgeon AF; McIntyre L; Fergusson DA
    CMAJ; 2007 Sep; 177(7):725-34. PubMed ID: 17823140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia and response to epoetin alfa: the cause of anemia matters!
    Dharmarajan TS
    J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic research in the intensive care unit: an unmet need.
    Haas CE; Forrest A
    Crit Care Med; 2006 Jun; 34(6):1831-3. PubMed ID: 16714989
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting anemia with erythropoietin during critical illness.
    Cook D; Crowther M
    N Engl J Med; 2007 Sep; 357(10):1037-9. PubMed ID: 17804850
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract]   [Full Text] [Related]  

  • 11. Erythropoietin use in the critically ill: current evidence.
    Warrillow SJ
    Crit Care Resusc; 2008 Sep; 10(3):257-60. PubMed ID: 18798726
    [No Abstract]   [Full Text] [Related]  

  • 12. Epoeitin alfa use in children undergoing myelosuppressive chemotherapy.
    Waxman IM
    J Clin Oncol; 2007 Mar; 25(7):919; author reply 919-20. PubMed ID: 17327622
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment: use of epoetin alfa in critically ill patients.
    Darveau M; Notebaert E
    Ann Pharmacother; 2004; 38(7-8):1325-6. PubMed ID: 15161948
    [No Abstract]   [Full Text] [Related]  

  • 14. [A deal with the Devil and Beelzebub].
    Heinzl S
    Med Monatsschr Pharm; 2003 May; 26(5):145. PubMed ID: 12784499
    [No Abstract]   [Full Text] [Related]  

  • 15. Epoetin alfa in the critically ill: What dose? Which route?
    Napolitano LM
    Crit Care Med; 2009 Apr; 37(4):1501-3. PubMed ID: 19318838
    [No Abstract]   [Full Text] [Related]  

  • 16. Epoetin alfa: future directions and future research.
    Ludwig H; Hudis CA; Goss G; Leyland-Jones B
    Oncologist; 2004; 9 Suppl 5():70-3. PubMed ID: 15591424
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic kidney disease, anemia, and epoetin.
    Go AS; Ayus JC
    N Engl J Med; 2007 Mar; 356(9):957; author reply 958-9. PubMed ID: 17338046
    [No Abstract]   [Full Text] [Related]  

  • 18. The first biosimilar epoetin: but how similar is it?
    Schellekens H
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):174-8. PubMed ID: 18057303
    [No Abstract]   [Full Text] [Related]  

  • 19. Taking the sub Q route in anemia management.
    Licht M; Eastman L; Kauffman S; Crooks P; Yeoh H
    Nephrol News Issues; 2001 Feb; 15(3):19-22, 24. PubMed ID: 12098964
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic kidney disease, anemia, and epoetin.
    Ashrani AA; Rajkumar SV
    N Engl J Med; 2007 Mar; 356(9):957-8; author reply 958-9. PubMed ID: 17338048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.